Juergen Krauss

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Niels Halama, Inka Zoernig, Anna Berthel et al. · Cancer Cell · 2016 · 494 citations · Full text

Medicine, Immunology, Oncology +11

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

Beate Schultheis, Gunnar Folprecht, Jan Kuhlmann et al. · Annals of Oncology · 2013 · 93 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme

Juergen Krauss, Michaela A.E. Arndt, Zhongyu Zhu et al. · British Journal of Cancer · 2004 · 31 citations · Full text

Pharmacy, Molecular Biology, Oncology +16

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

Dirk Strumberg, Beate Schultheis, M. E. Scheulen et al. · International Journal of Clinical Pharmacology and Therapeutics · 2010 · 22 citations

Pharmacy, Oncology, Pharmacokinetics +12

Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.

Beate Schultheis, Gunnar Folprecht, Jan Kuhlmann et al. · Journal of Clinical Oncology · 2011 · 13 citations

Medicine, Oncology, Pharmacology +12